Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 21666719 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Angus L, et al. (2012) Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Oncogene 31, 238-50 21666719
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S909-p - LATS1 (human)
Orthologous residues
LATS1 (human): S909‑p, LATS1 (mouse): S908‑p, LATS1 (rat): S909‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  MCF10A1 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FRMD6 (human) increase FERM domain of FRMD6 is sufficient for increase in phosphorylation
FRMD6 (human) increase shFRMD6 inhibits

T183-p - MST1 (human)
Orthologous residues
MST1 (human): T183‑p, MST1 (mouse): T183‑p, MST1 (rat): T183‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  MCF10A1 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FRMD6 (human) increase FERM domain of FRMD6 is sufficient for increase in phosphorylation
FRMD6 (human) increase
Merlin (human) FRMD6 (human) augment treatment-induced increase
Ezrin (human) no change compared to control
Merlin (human) increase slight increase
Ezrin (human) FRMD6 (human) inhibit treatment-induced increase
Ezrin (human), Merlin (human) decrease
Ezrin (human), Merlin (human) FRMD6 (human) inhibit treatment-induced increase
FRMD6 (human) increase shFRMD6 inhibits

T180-p - MST2 (human)
Orthologous residues
MST2 (human): T180‑p, MST2 (mouse): T180‑p, MST2 (rat): T180‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  MCF10A1 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FRMD6 (human) increase FERM domain of FRMD6 is sufficient for increase in phosphorylation
FRMD6 (human) increase
Merlin (human) FRMD6 (human) augment treatment-induced increase
Ezrin (human) no change compared to control
Merlin (human) increase slight increase
Ezrin (human) FRMD6 (human) inhibit treatment-induced increase
Ezrin (human), Merlin (human) decrease
Ezrin (human), Merlin (human) FRMD6 (human) inhibit treatment-induced increase
FRMD6 (human) increase shFRMD6 inhibits

S127-p - YAP1 (human)
Orthologous residues
YAP1 (human): S127‑p, YAP1 iso2 (human): S127‑p, YAP1 iso3 (human): S127‑p, YAP1 (mouse): S112‑p, YAP1 (rat): S112‑p, YAP1 iso3 (rat): S112‑p, YAP1 (sheep): S42‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  MCF10A1 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FRMD6 (human) increase FERM domain of FRMD6 is sufficient for increase in phosphorylation
FRMD6 (human) increase shFRMD6 inhibits
Downstream Regulation
 Effect of modification (process):  cell growth, inhibited


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.